viewReNeuron Group PLC

ReNeuron shares sharply higher after £68.4 million placing

The stem cell therapy group, ReNeuron, was one of the best performers on the AIM market after a successful placing which had the backing of star find manager, Neil Woodford. The CFO, Michael Hunt, tells Proactiveinvestors that the  placing, which was priced at a premium to the market price,  was also buoyed up by  continued support from existing investors and positive sentiment towards the Biotech sector. Woodford, who runs 2 Biotech funds raised his holding in ReNeuron to 35.5% after buying £32 million of the new shares. The funds will be sufficient to pay for ReNeuron’s existing therapeutic programmes through to 2019 and also early development of a new exosome nanomedicine platform targeting cancer.

Quick facts: ReNeuron Group PLC

Price: 128.5 GBX

Market: LSE
Market Cap: £40.91 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...



ReNeuron seeing increased interest across its assets from potential licensee...

ReNeuron Group PLC (LON: RENE) CFO Michael Hunt sat down with Proactive Investors at the 11th Annual Biotech Showcase in San Francisco. The UK-based developer of cell-based therapeutics in is the U.S. engaging with U.S. investors, and is looking to build out its business development...

on 01/11/2019

2 min read